Skip to main content

Tirzepatide vs Retatrutide

Both Tirzepatide and Retatrutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

Tirzepatide

Evidence A+

Tirzepatide (Mounjaro / Zepbound)

A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.

View full Tirzepatide profile →

Retatrutide

Evidence A

Retatrutide (LY3437943)

Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.

View full Retatrutide profile →

Side-by-Side

AttributeTirzepatideRetatrutide
Evidence GradeA+A
FDA StatusFDA-approved for weight management and type 2 diabetesNot FDA-approved — Phase 3 trials (TRIUMPH program) for obesity
Typical Dose2.5–15 mg weekly (subcutaneous injection)Trial range: 1–12 mg weekly (subcutaneous)
Clinics Indexed1,85012
Categoriesweight-loss, metabolicweight-loss, metabolic

Key reported benefits — Tirzepatide

  • Superior weight loss
  • Dual hormone targeting
  • Blood sugar control
  • Reduced cardiovascular risk

Key reported benefits — Retatrutide

  • Highest reported weight loss
  • Triple incretin/glucagon mechanism
  • Metabolic improvement

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons